Compare Danaher Corporation (DHR) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs MasterCard Inc — how do they compare? Danaher Corporation trades at $207 (market cap $145.83B), while MasterCard Inc trades at $560.89 (market cap $491.83B). The key difference: MasterCard Inc is far larger — about 3.4× Danaher Corporation's market cap, and Danaher Corporation pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| DHR | MA | |
|---|---|---|
Market Cap | $145.83B | $491.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $598.96 |
52-Week Low | $161.91 | $471.55 |
Enterprise Value | $168.04B | $504.86B |
Dividend Yield | 0.77% | 0.62% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Mastercard (MA) trades at $559.88, down 0.58% today, with strong technical support at $559 and resistance at $566. The stock shows robust fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and revenue growth accelerating to $32.79B in 2025. Analysts maintain a bullish consensus, with 79% buy ratings and a $660.85 price target, while institutional buying activity remains positive, as noted in recent SEC filings.
Outlook is positive due to consistent earnings beats, high profitability margins, and strategic initiatives in digital payments and AI. Risks include competition from emerging payment technologies like stablecoins, as highlighted by The Motley Fool on April 10, 2026, and elevated valuation multiples such as a P/E of 30.88, which may limit near-term upside if growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
